Roisin M. Connolly, M.B., B.Ch.,
Lead investigator for E2112 Study.
Assistant Professor of Oncology,
Johns Hopkins University,
The purpose of this study was to find ways to keep hormone-resistant tumors responding to hormone therapies for longer periods of time. This phase III clinical trial aimed to confirm what was found in a previous trial: that patients who received a standard hormonal treatment, exemestane (Aromasin), together with an investigational drug called entinostat, lived longer without the breast cancer growing or spreading, versus exemestane (Aromasin) alone. This trial, if positive, could potentially lead to a new FDA-approved treatment option that may help some patients live longer, experience symptom relief, or improve their quality of life.
The researchers wanted to enroll up to 107 volunteers and used the Army of Women (AOW) as one of their recruitment sources. The Call to Action for this study was sent to AOW members on May 23, 2017, and the researchers closed enrollment on October 5, 2018. The AOW provided them with four participants who were interested in enrolling in the study.